Verona Pharma stock hits all-time high at 104.83 USD

Verona Pharma (NASDAQ:VRNA) PLC ADR has reached an all-time high, with its stock price hitting 104.83 USD, pushing its market capitalization to $7.92 billion. According to InvestingPro data, analysts have set price targets ranging from $90 to $170 for the stock. This milestone marks a significant achievement for the company, reflecting substantial investor confidence and market performance. Over the past year, Verona Pharma’s stock has experienced a remarkable surge, with a 1-year return exceeding 409%. InvestingPro analysis reveals impressive gross profit margins of nearly 95% and a strong liquidity position with a current ratio of 8.86. This impressive growth trajectory highlights the company’s robust progress and strategic advancements in its sector, attracting increased attention from investors and analysts alike. As Verona Pharma continues to innovate and expand its market presence, with analysts forecasting 9.07% revenue growth, stakeholders will be keenly observing how the company capitalizes on this momentum moving forward. Discover 13 additional key insights about VRNA with a InvestingPro subscription, including detailed valuation metrics and growth indicators.

In other recent news, Merck (NSE:PROR) is reportedly nearing a $10 billion acquisition of Verona Pharma, with an offer of $107 per share, representing a 23% premium over Verona’s recent closing price. This potential acquisition has yet to be officially announced but would expand Merck’s portfolio in the respiratory disease treatment sector. Meanwhile, Verona Pharma’s COPD treatment, OHTUVAYRE, continues to perform well in the market. Piper Sandler reiterated its Overweight rating on Verona Pharma, increasing the price target to $160 due to the drug’s successful launch and strong refill data. Analysts project OHTUVAYRE’s sales to reach $91.8 million in the second quarter of 2025, with an estimated $409.1 million for the full year. Cantor Fitzgerald also maintained an Overweight rating, emphasizing the potential for OHTUVAYRE to become a franchise worth over $4 billion at peak sales. Jefferies raised its price target for Verona Pharma to $110, citing strong sales growth for OHTUVAYRE and the potential for the company to achieve profitability in the second quarter of 2025. These developments highlight a period of significant activity and potential growth for Verona Pharma.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.